JSC R-pharm Pharmaceutical Import Profile — Russia (DGFT 2022–2026)

Name: JSC R-pharm Pharmaceutical Import Records from India — 2 Products, $3.9M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

JSC R-pharm — Pharmaceutical Importer Profile (2026) | 2 Products, $3.9M Trade | TransData Nexus

JSC R-pharm

Pharmaceutical Importer · Russia · Advanced Oncology Focus · $3.9M Total Trade · DGFT Verified

JSC R-pharm is a pharmaceutical importer based in Russia with a total trade value of $3.9M across 2 products in 1 therapeutic categories. Based on 77 verified import shipments from Indian Customs (DGFT) records, JSC R-pharm is the #1 buyer in 2 products including Bevacizumab, Rituximab. JSC R-pharm sources from 2 verified Indian suppliers, with Dr.reddy's Laboratories Limited accounting for 100.0% of imports.

JSC R-pharm — Import Portfolio & Supplier Network

JSC R-pharm import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to JSC R-pharm?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr.reddy's Laboratories Limited	$3.0M	63	100.0%
Dr Reddys Laboratories Limited	$611	4	0.0%

JSC R-pharm sources from 2 verified Indian suppliers across .

What Formulations Does JSC R-pharm Import?

Formulation	Value	Ships
Bevacizumab substance-frozen solution	$1.1M	22
Rituximab working cell	$100.0K	2
Bevacizumab substance-frozen solution concentration 34.0 MG/ML with buffer solution 28,404 l(qty:965.736 gms)	$100.0K	2
Bevacizumab substance-frozen solution concentration 36.0 MG/ML with buffer solution 28,040 l(qty:1009.440 gms)	$100.0K	2
Tbism-1(trastuzumab intermediate)(qty:3826.8 gms)	$50.0K	1
Bevacizumab wcb(qty:2 vials)(net weight:2 gms)	$50.0K	1
Rituximab wcb(working cell bank)(qty:3 vials)	$50.0K	1
Bevacizumab wcb(working cell bank)(qty:3vials)	$50.0K	1
Rituximab wcb(working cell bank)(qty:5 vials)	$50.0K	1
Rituximab substance-frozen solution concentration 20.5 MG/ML with buffer solution 116,466 l(qty: 2387.553 gms)	$50.0K	1
Rituximab substance-frozen solution concentration 19.6 MG/ML with buffer solution 123,350 l(qty: 2417.66 gms)	$50.0K	1
Rituximab substance-frozen solution concentration 19 MG/ML with buffer solution123,355 l(qty: 2343.745 gms)	$50.0K	1
Bevacizumab substance-frozen solution concentration 33.0 MG/ML with buffer solution 26,284 l(qty:867.372 gms)	$50.0K	1
Bevacizumab substance-frozen solution concentration 33.0 MG/ML with buffer solution 27,050 l(qty:892.650 gms)	$50.0K	1
Bevacizumab substance-frozen solution concentration 34.0 MG/ML with buffer solution 25,207 l(qty:857.038 gms)	$50.0K	1

JSC R-pharm imports 42 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Bevacizumab	Advanced Oncology	$3.3M	66	5.4%	1
2	Rituximab	Advanced Oncology	$550.0K	11	2.9%	1

JSC R-pharm imports 2 pharmaceutical products across 1 categories into Russia totaling $3.9M. The company is the #1 buyer for 2 products: Bevacizumab, Rituximab.

JSC R-pharm — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

JSC R-Pharm, established in 2001 by Alexey Repik, is a prominent Russian multinational pharmaceutical company headquartered in Moscow. The company specializes in the research, development, manufacturing, and distribution of innovative medicines, particularly in the fields of oncology and immunology. R-Pharm operates across various regions, including Russia, the CIS, the USA, Germany, Japan, Turkey, and the Middle East and North Africa, employing over 3,500 professionals across more than 50 branches.

In 2017, Japanese Corporation Mitsui & Co., Ltd. acquired a 10% stake in JSC R-Pharm, reflecting the company's expanding international presence. The company's mission is to enhance the accessibility of modern medicines for patients in Russia and globally. R-Pharm's product portfolio includes treatments for various therapeutic areas, such as oncology, hematology, cardiology, immunology, and infectious diseases.

2Distribution Network

R-Pharm's distribution network is extensive, encompassing multiple manufacturing sites and a wide-reaching logistics infrastructure. In Russia, the company operates state-of-the-art facilities in Yaroslavl, Rostov, Moscow, Kostroma, and Dubna. Additionally, R-Pharm owns a plant in Illertissen, Germany, acquired in June 2014, which continues to produce Pfizer products under an agreement for the first five years.

The company's logistics capabilities support its operations across Russia and internationally, ensuring efficient distribution of pharmaceutical products. R-Pharm's geographic coverage extends to the CIS, USA, Germany, Japan, Turkey, and the Middle East and North Africa, facilitated by its over 70 branches and representative offices.

3Industry Role

JSC R-Pharm plays a multifaceted role in Russia's pharmaceutical supply chain. As a primary wholesaler, it distributes a wide range of pharmaceutical products to various healthcare institutions. The company also functions as a parallel importer, sourcing medicines from international markets to meet domestic demand. Additionally, R-Pharm serves as a hospital supplier, providing specialized medical products and equipment to healthcare facilities. Its comprehensive operations encompass manufacturing, research and development, and distribution, positioning R-Pharm as a key player in the Russian pharmaceutical industry.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — JSC R-pharm

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

JSC R-Pharm's sourcing strategy exhibits a high degree of concentration, particularly in its imports from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $3.9 million USD from India, comprising 77 shipments. The top two products imported were Bevacizumab ($3.3 million, 5.4% share) and Rituximab ($550,000, 2.9% share), both sourced exclusively from DR.REDDY'S LABORATORIES LIMITED.

This single-source dependency indicates a strategic choice to maintain a consistent supply of these critical oncology treatments. The absence of alternative suppliers for these products suggests a stable and long-term relationship between R-Pharm and DR.REDDY'S LABORATORIES LIMITED. However, this concentration also exposes R-Pharm to potential risks associated with supply chain disruptions, such as production delays or regulatory changes affecting the supplier.

2Supply Chain Resilience

JSC R-Pharm's supply chain resilience is closely tied to its sourcing strategy. The company's reliance on a single supplier for key oncology products like Bevacizumab and Rituximab may limit its ability to quickly adapt to supply chain disruptions. The lack of backup suppliers for these products suggests a potential vulnerability in the event of unforeseen issues with DR.REDDY'S LABORATORIES LIMITED.

Additionally, the diversity of formulations imported from India, totaling 42 unique formulations, indicates a broad sourcing approach. However, the concentration of imports in the Advanced Oncology therapeutic category (100%) suggests that R-Pharm's supply chain is heavily focused on this segment. This focus may impact the company's ability to diversify its product offerings and mitigate risks associated with overreliance on a single therapeutic area.

Importing Pharmaceuticals into Russia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Russia

1Regulatory Authority & Framework

In Russia, the circulation of medicinal products is regulated by the Federal Service for Surveillance in Healthcare (Roszdravnadzor), which oversees the registration, import, and distribution of pharmaceuticals. The primary legislation governing pharmaceutical imports is Federal Law No. 61-FZ dated April 12, 2010, "On the Circulation of Medicinal Products." This law outlines the procedures for importing medicines, including the requirement for imported medicines to be included in the state register.

The marketing authorization pathway for Indian generics involves obtaining registration from Roszdravnadzor, which includes submitting comprehensive documentation on the product's quality, safety, and efficacy. The registration process ensures that imported generics meet Russian standards and are authorized for sale and distribution within the country.

2Import Licensing & GMP

Import licensing requirements in Russia stipulate that all pharmaceutical products must be registered with Roszdravnadzor before they can be imported and marketed. This process involves providing detailed information about the product, including manufacturing processes, quality control measures, and clinical data. Compliance with Good Manufacturing Practice (GMP) standards is mandatory, and foreign manufacturers must provide certificates of GMP compliance from recognized authorities, such as the European Union or the World Health Organization.

JSC R-pharm — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

JSC R-Pharm's focus on the Advanced Oncology therapeutic category aligns with the growing demand for cancer treatments in Russia. The importation of Bevacizumab and Rituximab addresses critical needs in the oncology sector, providing patients with access to essential therapies. This strategic focus is driven by the high prevalence of cancer and the necessity for effective treatment options within the Russian healthcare system.

2Sourcing Profile

R-Pharm's sourcing strategy emphasizes the procurement of generic drugs, particularly in the oncology segment. The company's preference for finished pharmaceutical formulations over active pharmaceutical ingredients (APIs) indicates a focus on ready-to-use products that can be directly distributed to healthcare providers. India's role as a supplier aligns with its reputation for producing high-quality generics, making it a strategic partner for R-Pharm's procurement needs.

3Market Positioning

Based on its product mix, JSC R-Pharm primarily serves the hospital segment of the Russian market. The importation of specialized oncology treatments positions the company as a key supplier to healthcare institutions requiring advanced therapies. While R-Pharm's products may also be available through retail pharmacies, the focus on complex treatments suggests a primary orientation towards hospital and specialized medical care.

Seller's Guide — How to Become a Supplier to JSC R-pharm

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with JSC R-Pharm, particularly in the oncology segment. By offering complementary products or alternative formulations, Indian exporters can address potential gaps in R-Pharm's current sourcing strategy. Ensuring consistent product quality, compliance with Russian regulatory standards, and establishing

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — JSC R-pharm

What products does JSC R-pharm import from India?

JSC R-pharm imports 2 pharmaceutical products across 1 categories. Top imports: Bevacizumab ($3.3M), Rituximab ($550.0K).

Who supplies pharmaceuticals to JSC R-pharm from India?

JSC R-pharm sources from 2 verified Indian suppliers. The primary supplier is Dr.reddy's Laboratories Limited (100.0% of imports, $3.0M).

What is JSC R-pharm's total pharmaceutical import value?

JSC R-pharm's total pharmaceutical import value from India is $3.9M, based on 77 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does JSC R-pharm focus on?

JSC R-pharm imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full JSC R-pharm Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.